modelDactinomycin
Extends from Pharmacolibrary.Drugs.ATC.L.L01DA01.
Information
| name: | Dactinomycin | |
| ATC code: | L01DA01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 15 | mg |
| volume of distribution: | 0.45 | L |
| clearance: | 0.037 | L/kg/h |
| other parameters in model implementation | ||
Dactinomycin (also known as actinomycin D) is a cytotoxic antibiotic used mainly as an antineoplastic agent. It is approved for use in the treatment of various cancers, including Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, and gestational trophoblastic neoplasia. It works by binding to DNA and inhibiting RNA synthesis, thus preventing cell replication.
Pharmacokinetics
Pharmacokinetic parameters reported in adult cancer patients following intravenous bolus administration. Data primarily from clinical studies in adult and paediatric patient populations with various solid tumors.
References
Veal, GJ, et al., & Boddy, AV (2005). Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clinical cancer research : an official journal of the American Association for Cancer Research 11(16) 5893–5899. DOI:10.1158/1078-0432.CCR-04-2546 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16115931
Mondick, JT, et al., & Barrett, JS (2008). Population pharmacokinetic investigation of actinomycin-D in children and young adults. Journal of clinical pharmacology 48(1) 35–42. DOI:10.1177/0091270007310383 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18094218
Moore, DH, et al., & Reid, GC (1999). Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecologic oncology 75(3) 473–475. DOI:10.1006/gyno.1999.5652 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10600310
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)